WO2001026619A2 - Composition, in particular cosmetic, containing dihydroepiandosterone (dhea) and a desquamative agent - Google Patents
Composition, in particular cosmetic, containing dihydroepiandosterone (dhea) and a desquamative agent Download PDFInfo
- Publication number
- WO2001026619A2 WO2001026619A2 PCT/FR2000/002682 FR0002682W WO0126619A2 WO 2001026619 A2 WO2001026619 A2 WO 2001026619A2 FR 0002682 W FR0002682 W FR 0002682W WO 0126619 A2 WO0126619 A2 WO 0126619A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- function
- composition according
- composition
- skin
- chosen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- composition in particular cosmetic, containing DHEA and a scaling agent
- the present invention relates to a composition containing DHEA, in combination with at least one scaling agent.
- DHEA dehydroepiandrosterone
- Exogenous DHEA administered topically or orally, is particularly known for its ability to promote keratinization of the epidermis (JP-07 196 467) and to treat dry skin by increasing endogenous production and sebum secretion and by thus reinforcing the barrier effect of the skin (US-4,496,556). It has also been described in US Pat. No. 5,843,932 the use of DHEA for remedying atrophy of the dermis by inhibiting the loss of collagen and connective tissue.
- the subject of the present invention is therefore a new composition
- a composition comprising, in a physiologically acceptable medium, (a) DHEA, and (b) at least one desquamating agent chosen from retinoids, acyl derivatives of salicylic acid, inhibitors of HMG-CoA reductase and sugar derivatives.
- DHEA has the following formula (I):
- the DHEA which can be used according to the invention is for example available from the company AKZO NOBEL.
- the concentration of DHEA in the composition according to the invention is advantageously between 0.001% and 20% by weight, preferably between 0.01 and 10% by weight, more preferably between 0.1 and 3% by weight, relative to the total weight of the composition.
- retinoids such as retinoic acid (all-trans or 13-cis) and its derivatives, retinaldehyde, retinol (vitamin A) and its esters such as retinol palmitate, acetate can be used. retinol and retinol propionate, and mixtures thereof.
- the desquamating agent can be an acylated derivative of salicylic acid, in particular a 5-acyl-saiicylic acid such as n-octanoyl-5-saiicylic acid, n-dodecanoyl-5-salicylic acid and n-decanoyl-5-salicylic acid, in free or salified form, in particular in the form of salts obtained by salification with a mineral or organic base. It is particularly preferred to use n-octanoyl-5-salicylic acid.
- This compound can be prepared as described in application FR-2,581,542 in the name of the Applicant.
- the desquamating agent can be chosen from HMG-CoA reductase inhibitors.
- HMG-CoA-reductase inhibitors can be, for example, the following compounds: mevastatin, lovastatin, pravastatin, simvastatin, fluvastatin, dalvastatin, and their derivatives and salts, in particular their sodium salts.
- the desquamating agent can be a sugar derivative, in particular a carbohydrate or carbohydrate derivative corresponding to formula (I),
- A represents a chain composed of one to twenty carbohydrate units or carbohydrate derivatives, each comprising 3 to 6 carbon atoms, linked together, preferably by acetal bridges, each of these units possibly being substituted, for example by a halogen , by an amino function, an acid function, an ester function, a thiol, an alkoxy function, a thio-ether function, a thio-ester function, an amide function, a carbamate function and / or a urea function,
- R represents an alkyl chain or an alkenyl chain, comprising from 4 to 24 carbon atoms, branched or linear, which can be interrupted by ether bridges, optionally carrying a hydroxyl function, a carboxylic acid function, an amino function, an ester function, an acyloxy function, an amide function, an ether function, a carbamate function and / or a urea function,
- X represents a function linking R and A, such as for example an amine, ether, amide, ester, urea, carbamate, thioester, thioether or sulfonamide function.
- sugar derivatives there may be mentioned N-butanoyI-D-glucosamine, N-octanoyl-D-glucosamine, N-octyloxycarbonyl-N-methyl-D-glucamine, N-2-ethyl-hexyloxycarbonyl-N -methyl-D-glucamine, 6-0-octanoyl-D-glucose, 6'-0-dodecanoyl-D-maltose and 6'-0-octanoyl-D-maltose, the latter compound being particularly preferred.
- the scaling agent can be used in the composition according to the invention in an amount representing from 0.1 to 10%, preferably from 0.1 to 5% and, better still, from 0.5 to 3% by weight of the total weight of the composition.
- composition according to the invention can be in all dosage forms normally used for topical application to the skin, in particular in the form of an oily solution, of an oil-in-water or water-in-oil or multiple emulsion.
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel. It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick. It can be used as a care product and / or as a skin makeup product.
- the composition of the invention may also contain the adjuvants usual in the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matter.
- the amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and / or into the nanoparticles.
- These adjuvants, as well as their concentrations must be such that they do not harm the advantageous properties of the combination of active agents according to the invention.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the fats, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the co-emulsifier are preferably present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
- oils and in particular mineral oils such as mineral oils (petroleum jelly oil), oils of vegetable origin (oil) can be used. avocado, soybean oil), oils of animal origin (lanolin), synthetic oils (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers).
- Fatty alcohols such as cetyl alcohol, fatty acids, waxes and gums and in particular silicone gums can also be used as fats.
- emulsifiers and coemulsifiers which can be used in the invention, mention may, for example, be made of fatty acid and polyethylene glycol esters such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate; polyol fatty acid esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
- fatty acid and polyethylene glycol esters such as PEG-100 stearate, PEG-50 stearate and PEG-40 stearate
- polyol fatty acid esters such as glyceryl stearate, sorbitan tristearate and oxyethylenated sorbitan stearates available under the trade names Tween® 20 or Tween® 60, for example; and their mixtures.
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacryiamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids and hydrophobic silica.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkyl acrylate copolymers
- polyacryiamides polysaccharides
- natural gums and clays and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids and hydrophobic silica.
- composition according to the invention also contains a progestogen, such as pregnenoion and 17-OH progesterone.
- composition according to the invention finds in particular an application in the prevention and the treatment of the cutaneous signs of chronological or actinic aging.
- the present invention therefore also relates to the cosmetic use of the composition mentioned above for preventing or treating the skin signs of chronological or actinic aging, in particular:
- composition according to the invention comprises an effective amount of DHEA, sufficient to obtain the desired effect, and a physiologically acceptable medium.
- phase A1, A2 and B are prepared separately by mixing their constituents under hot conditions, with stirring. Phases A1 and A2 are mixed hot, then phase B is added to them. The mixture thus obtained was transferred to a high pressure homogenizer where it is subjected to three passages at 600 bars before incorporation of phase C.
- This composition can be used in twice-daily applications to prevent or treat the signs of aging such as wrinkles and fine lines, loss of radiance and dryness of the skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2000276682A AU2000276682A1 (en) | 1999-10-13 | 2000-09-28 | Composition, in particular cosmetic, containing dihydroepiandosterone (dhea) anda desquamative agent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9912773A FR2799645B1 (en) | 1999-10-13 | 1999-10-13 | USE OF DHEA OR ITS PRECURSORS OR METABOLIC DERIVATIVES AS DEPIGMENTANT |
FR99/12773 | 1999-10-13 | ||
FR00/09228 | 2000-07-13 | ||
FR0009228A FR2799649B1 (en) | 1999-10-13 | 2000-07-13 | COMPOSITION, PARTICULARLY COSMETIC, CONTAINING DHEA AND A DESQUAMANT AGENT |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001026619A2 true WO2001026619A2 (en) | 2001-04-19 |
WO2001026619A3 WO2001026619A3 (en) | 2001-12-06 |
Family
ID=26212532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/002682 WO2001026619A2 (en) | 1999-10-13 | 2000-09-28 | Composition, in particular cosmetic, containing dihydroepiandosterone (dhea) and a desquamative agent |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2000276682A1 (en) |
FR (1) | FR2799649B1 (en) |
WO (1) | WO2001026619A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826577A1 (en) * | 2001-06-29 | 2003-01-03 | Oreal | USE OF LYS-PRO-VAL TRIPEPTIDE (KPV) TO ENHANCE THE BARRIER FUNCTION OF THE SKIN |
FR2827767A1 (en) * | 2001-07-27 | 2003-01-31 | Oreal | Aqueous suspension of nanocapsules containing dehydroepiandrosterone, useful in cosmetic or dermatological compositions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2868309B1 (en) * | 2004-04-02 | 2006-05-26 | Oreal | COSMETIC USE OF AT LEAST ONE HMG-COA-REDUCTASE INHIBITOR AS AN AGENT FOR PREVENTING AND / OR COMBATTING EXPRESSION WRINKLES |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
US5883086A (en) * | 1997-05-02 | 1999-03-16 | Craft; John C. | DHEA-containing nutritional supplement |
US5900242A (en) * | 1995-01-26 | 1999-05-04 | Societe L'oreal S.A. | Cosmetic/dermatological skin care compositions comprising S-DHEA |
US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
-
2000
- 2000-07-13 FR FR0009228A patent/FR2799649B1/en not_active Expired - Fee Related
- 2000-09-28 AU AU2000276682A patent/AU2000276682A1/en not_active Abandoned
- 2000-09-28 WO PCT/FR2000/002682 patent/WO2001026619A2/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4542129A (en) * | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
US6093706A (en) * | 1992-03-04 | 2000-07-25 | Bioresponse, L.L.C. | Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders |
US5900242A (en) * | 1995-01-26 | 1999-05-04 | Societe L'oreal S.A. | Cosmetic/dermatological skin care compositions comprising S-DHEA |
US5883086A (en) * | 1997-05-02 | 1999-03-16 | Craft; John C. | DHEA-containing nutritional supplement |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2826577A1 (en) * | 2001-06-29 | 2003-01-03 | Oreal | USE OF LYS-PRO-VAL TRIPEPTIDE (KPV) TO ENHANCE THE BARRIER FUNCTION OF THE SKIN |
WO2003002086A2 (en) * | 2001-06-29 | 2003-01-09 | L'oreal | Use of the tripeptide lys-pro-val(kpv) for improving the skin barrier function |
WO2003002086A3 (en) * | 2001-06-29 | 2003-04-10 | Oreal | Use of the tripeptide lys-pro-val(kpv) for improving the skin barrier function |
FR2827767A1 (en) * | 2001-07-27 | 2003-01-31 | Oreal | Aqueous suspension of nanocapsules containing dehydroepiandrosterone, useful in cosmetic or dermatological compositions |
WO2003013445A1 (en) * | 2001-07-27 | 2003-02-20 | L'oreal | Nanocapsules containing a steroid for cosmetic compositions |
Also Published As
Publication number | Publication date |
---|---|
FR2799649A1 (en) | 2001-04-20 |
AU2000276682A1 (en) | 2001-04-23 |
WO2001026619A3 (en) | 2001-12-06 |
FR2799649B1 (en) | 2005-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2174598C (en) | Use of an inhibitor of an hmg-coenzyme-a reductase to prevent aging of the skin or to stimulate the process of epidermal renewal | |
EP0662318B1 (en) | Cosmetic and/or dermatological composition containing salicylic acid derivatives and the solubilisation process of these derivatives | |
EP0771557B1 (en) | Use of ascorbic acid as the active agent for the treatment of seborrhea in a cosmetic and/or dermatalogical composition | |
EP1057809B1 (en) | Carbonate derivatives of retinol, process for their preparation and utilisations | |
WO1996026711A1 (en) | Nitric oxide synthase inhibitors | |
EP1269986B1 (en) | Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, and corresponding uses and processes | |
CA2343426A1 (en) | Compound, specificially for cosmetic use, containing a steroid and a 2-alkyl acanol or an ester | |
EP0756866B1 (en) | Use of benzoic acid derivatives for stimulating the renewal of the epidermis and for treating the skin | |
FR2818148A1 (en) | COMPOSITION, IN PARTICULAR COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE ISOFLAVONOID | |
CA2099473C (en) | Depigmenting cosmetic and/or dermatologic composition containing a di- or tri-cafeoylquinic acid or a blend of these acids | |
EP1172094B1 (en) | Composition, particularly for cosmetics, comprising DHEA and/or precursor or derivative, and at least a compound which increases the synthesis of glycosaminoglycans | |
FR2798855A1 (en) | Compositions comprising organo-metallic complexes, especially of calcium or strontium, are used to reduce skin irritation | |
FR2780646A1 (en) | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING SALICYLIC ACID DERIVATIVES AND METHOD FOR INTRODUCING DERIVATIVES THEREOF IN AQUEOUS COMPOSITION | |
EP1303253B1 (en) | Composition, in particular cosmetic, comprising dhea and/or a precursor or derivative thereof, combined with at least a glycation inhibiting agent | |
EP1303250A1 (en) | Composition, in particular cosmetic, containing dhea and isoflavonoid | |
WO2001026619A2 (en) | Composition, in particular cosmetic, containing dihydroepiandosterone (dhea) and a desquamative agent | |
JP2000212033A (en) | Composition for topically applying to skin and/or surface growing body of skin including at least one compound containing phenyloxime fragment | |
WO2002047645A1 (en) | Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least a peeling agent | |
WO2002047652A1 (en) | Composition containing 7-hydroxy dhea and/or 7-keto dhea and at least an antimicrobial agent | |
WO2002005779A1 (en) | Composition, in particular cosmetic, containing dhea and/or its precursors or derivatives, and a vitamin | |
FR2773074A1 (en) | Composition containing an alpha-hydroxy acid and a ceramide or ceramide precursor for topical treatment of dermatological disorders | |
FR2826273A1 (en) | Compositions, useful for depigmenting or bleaching hyperpigmented skin , comprise a compound of low solubility and a lipophilic amino acid derivative give stable emulsions | |
FR2801508A1 (en) | Topical compositions contain a HMG CoA-reductase inhibitor and a compound that completes its effect, for treatment of seborrhea and associated dermatoses | |
FR2818138A1 (en) | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE DEPIGMENTING AGENT | |
FR3142888A1 (en) | Cosmetic use of a combination of salicylic acid and/or its derivatives and/or their salts, sarcosine and an algae extract of marine origin to treat and/or prevent oily skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000966215 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000966215 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |